Shire announces Phase IIIb study results of Daytrana
Links shared publicly online about this topic.
- 1,637total visits
Shire announces Phase IIIb study results of Daytrana
Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).
View full resource at news-medical.net
Tags: Stroke, ADHD Medication, Thrombotic Event, Concerta, Metadate CD, Metadate ER, Methylin, Shire
Most Recently Shared on October 31, 2009 at 10:11 am By:
Stroke News: Shire announces Phase IIIb study results of Daytrana: Shire plc, the global specialty .. http://twurl.nl/ry1u35
Advertisement
